A phase 1 study by Creelan et al. [94] analyzed the combination of Gefitinib and Durvalumab on 56 EGFR TKI-naïve patients with EGFR mutation-positive locally advanced or metastatic NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.